

REFERENCES

1. Stevens DA. 1987. *Candida* Infections and the Host Status. ***Candida, The Growing Problem***. U.S.A. : Pfizer International.
2. Komshian SV, Uwaydah AK, Sobel JD, and Crane LR. 1989. Fungemia caused by *Candida* species and *Torulopsis glabrata* in the hospitalized patient : frequency, characteristics, and evaluation of factors influencing outcome. **Rev Infect Dis** 11: 379 – 390.
3. Jarvis WR, Edwards JR, Culver DH, *et al.* 1991. Nosocomial infection rates in adult and pediatric intensive care units in the United States. **Am J Med** 91(suppl 3B): 185s – 191s.
4. Banerjee SN, Emori TG, Culver DH, *et al.* 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980 – 1989. **Am J Med** 91(suppl 3B) : 86s – 89s.
5. Jarvis WR. 1995. Epidemiology of Nosocomial fungal infections, with Emphasis on *Candida* Species. **Clin Infect Dis** 20: 1526 – 1530.
6. Pfaller MA. 1994. Epidemiology and control of fungal infections. **Clin Infect Dis** 19(suppl 1) : s8 – s13.
7. Odds FC. 1988. Morphogenesis in *Candida albicans*. **Crit Rev Microbiol** 12: 45 – 93.
8. Akova M, Akalin HE, Uzan O, and Gur D. 1991. Emergence of *Candida krusei* infections after therapy with oropharyngeal candidiasis with fluconazole (letter). **Eur J Clin Microbiol Infect Dis** 10: 598 – 599.
9. Blinkhorn RJ, Adelstein D, and Spagnuolo PJ. 1989. Emergence of a new opportunistic pathogen, *Candida lusitanae*. **J Clin Microbiol** 27: 236 – 240.
10. Sanchez V, Vazquea JA, Barth – Jones D, Dembry L, Sobel JD, and Zervos MJ. 1993. Nosocomial acquisition of *Candida parapsilosis*: and epidemiologic study. **Am J Med** 94: 577 – 582.
11. Ponton J, *et al.* 2000. Emerging pathogens. **Med Mycol** 38 (suppl 1) : 225 – 236.

12. Vazquez JA, Sobel JD, Peng G, Steele – Moore L, Schuman P, Holloway W, and Neaton JD. 1999. Evolution of vaginal *Candida* species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of *Candida glabrata*? Terry Bein Community Programs for Clinical Research in AIDS (CPCRA). **Clin Infect Dis** 28(5) : 1025-31.
13. Kao AS, *et al.* 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. **Clin Infect Dis** 29 (5) : 1164-70.
14. Pfaller MA. 1996. Nosocomial Candidiasis : Emerging Species, reservoirs, and Modes of Transmission. **CID** 22(Suppl 2) : s89 – s92
15. Bodey GP. 1984. Candidiasis : a growing concern. **Am J Med** . 77: 1 – 48.
16. Sanjua'n R, Zueco J, Pe'rez J, Penarroya C, and Sentandreu R. 1996. A comparative study of the incorporation of a 1,6 – b- glucan and an O – glycosylated protein epitope into the cell wall of *Candida albicans*. **Microlbiol** 142 : 2255 – 2262.
17. Casadevall A, Cassone A , Bistoni F, Cutler JE, Magliani W, Murphy JW, Polonelli L, and Romani L. 1998. Antibody and / or cell – mediated immunity, protective mechanisms in fungal disease : and ongoing dilemma or an unnecessary dispute? **Med Mycol** 36 (Suppl.1): 95 – 105.
18. Fukazawa Y, Cassone A, Bistoni F, Howard DH, Kagaya K, Murphy JW, Cenci E, *et al.* 1994. Mechanisms of cell – mediated immunity in fungal infection. **J Med Vet Mycol** 32 (Suppl. 1): 123 – 131.
19. Klein RS, Harris CA, Small BC, Moll B, Lesser M, and Friedland GH. 1984. Oral candidiasis in high – risk patients as the initial manifestation of the acquired immunodeficiency syndrome. **N Engl J Med** 311: 354 – 358.
20. Casadevall A. 1995. Antibody immunity and invasive fungal infections. **Infect Immun** 65 : 4211 – 4218.
21. Cassone A, De Bernardis F, Ausiello CM, Gomez MJ, Boccanera M, La Valle R, and Torosantucci A. 1998. Immunogenic and protective *Candida albicans* constituents. **Res Immunol** 149 : 289 – 299.

22. Deeps GS, Jr. 1997. Prospects for the development of fungal vaccines. **Clin Microbiol Rev** 10: 585 – 596.
23. Dixon DJ, Casadevall A, Klein B, Mendoza L, Travassos L, and Deepe GS, Jr. 1998. Development of vaccines and their use in the prevention of fungal infections. **Med Mycol** 36(Suppl.1): 57 – 67.
24. Han Y, and Cutler JE. 1995. Antibody response that protects against disseminated candidiasis. **Infect Immun** 63: 2714 – 2719.
25. Han Y., Ulrich MA., and Cutler JE. 1999. *Candida albicans* mannan extract – protein conjugates induce a protective immune response against experimental candidiasis. **J Infect Dis** 179: 1477 – 1484.
26. Matthews RC. 1994. Pathogenicity determinants of *Candida albicans* : potential targets for immunotherapy? **Microbiol.** 140 : 1505 – 1511.
27. Tavares D, Ferreira P, Vilanova M, Videira A, and Arala – Chaves M. 1995. Immunoprotection against systemic candidiasis in mice. **Int Immunol.** 7: 785 – 796.
28. Martinez JP, Gil JL, Lopez – Ribot JL, and Chaffin WL. 1998. Serologic response to cell wall mannoproteins and proteins of *Candida albicans*. **Clin Microbiol Rev** 11: 121 – 141.
29. Sundstrom P, Jensen J, and Balish E. 1994. Humoral and cellular immune response to enolase after alimentary tract colonization or intravenous immunization with *Candida albicans*. **J Infect Dis** 170 : 390 – 395.
30. Rippon JW. 1988. Candidiasis and Pathogenic Yeasts. Wonsiewicz, M (ed.). **Medical Mycology** (3rd): 532 – 581.
31. Odds FC. 1988. **Candida and candidosis**. 2nd ed. Philadelphia, U.S.A: The W.B.Saunders Co.
32. Hadfield TL, Smith MB, Winn RE, Rinalde MG, and Guerra C. 1987. Mycoses caused by *C. lusitaniae*. **Rev Infect Dis** 9: 1006 – 1012.
33. Walker TS. 1999. Fungi that cause deep (systemic) mycoses; *aspergillus*, *blastomyces*, *candida*, *coccidioides*, *cryptococcus*, *histoplasma*, *mucor*, *paracoccidioides*, *rhizopus*, and other fungi. **Microbiol Rev.** U.S., W.B.Saunders. company: 134 – 141.

47. Cannon RD, and Chaffin WL. 1999. Oral colonization by *Candida albicans*. **Crit Rev Oral Biol Med** 10(3) : 359 – 83.
48. Gaur NK, *et al.* 1999. Overexpression of the *Candida albicans* *ALAI* gene in *Saccharomyces cerevisiae* results in aggregation following attachment of yeasts cells to extracellular matrix proteins, adherence properties similar to *Candida albicans*. **Infect Immun** 67 : 6040 – 6047.
49. Gaur NK, and Klotz SA. 1997. Expression, cloning and characterization of a *Candida albicans* *ALAI*, that confers adherence properties upon *Saccharomyces cerevisiae* for extracellular matrix proteins. **Infect Immun** 65 : 5289 – 5294.
50. Fu Y, *et al.* 1998. Expression of the *Candida albicans* gene *ALS 1* in *Saccharomyces cerevisiae* induces adherence to endothelial and epithelial cells. **Infect Immun** 66 : 1783 – 1786.
51. Staab JF, *et al.* 1999. Adhesive and mammalian transglutaminase properties of the *Candida albicans* *HWPI*. **Science** 283 : 1535 – 1538.
52. Gale C, *et al.* 1998. Linkage of adhesion, filamentous growth, and virulence in *Candida albicans* to a single gene, *INT 1*. **Science** 279 : 1355 – 1358.
53. Buurman C, *et al.* 1998. Molecular analysis of CaMnt 1p, a mannosyl transferase important for adhesion and virulence of *Candida albicans*. **Proc Natl Acad Sci USA** 95: 7670 – 7675.
54. Calderone RA, and Fonzi WA. 2001. Virulence factors of *Candida albicans*. **Trends Microbiol** 19(7) : 327 – 35.
55. Lo H-J, *et al.* 1997. Nonfilamentous *Candida albicans* mutants are avirulent. **Cell** 90 : 939 – 949.
56. Stoldt VR, *et al.* 1997. Efg 1p, an essential regulator of morphogenesis of the human pathogen *Candida albicans*, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. **EMBO J** 16 : 1982 – 1991.
57. Braun B, and Johnson AD. 1997. Control of filament formation in *Candida albicans* by the transcriptional repressor *TUPI*. **Sci** 277 : 105 – 109

58. Ishii N, *et al.* 1997. Biochemical characterization of Rbf 1p, a putative transcription factor of *Candida albicans*. **Microbiol** 143 : 429 – 435.
59. Brown DH, *et al.* 1999. Filamentous growth of *Candida albicans* in response to physical environmental cues and its regulation by the unique *CZF1* gene. **Mol Microbiol** 34 : 651 – 662.
60. Hube B. *et al.* 1997. Disruption of each of the secreted aspartyl proteinase genes *SAP1*, *SAP2*, and *SAP3* of *Candida albicans* attenuates virulence. **Infect Immun** 65: 3529 – 3538.
61. Sanglard D. *et al.* 1997. A triple deletion of the secreted aspartyl proteinase genes, *SAP4*, *SAP5*, and *SAP6* of *Candida albicans* causes attenuated virulence. **Infect Immun** 65: 3539 – 3546.
62. Calderone RA, and Braun PC. 1991. Adherence and receptor relationships of *Candida albicans*. **Microbiol Rev** 55: 1 – 20.
63. Klotz SA. 1992. Fungal adherence to the vascular compartment : a critical step in the pathogenesis of disseminated candidiasis. **Clin Infect Dis** 14: 340 – 347.
64. Fukayama M, and Calderone RA. 1991. Adherence of cell surface mutants of *Candida albicans* to buccal epithelial cells and analyses of the cell surface proteins of the mutants. **Infect Immun** 59: 1341 – 1345.
65. Ghannoum MA, Burns GR, Abu Elteen K, Radwan SS. 1986. Experimental evidence for the role of lipids in adherence of *Candida* spp. to human buccal epithelial cells. **Infect Immun** 54: 189 – 193.
66. Sawyer RT, Horst MN, Garner RE, Hudson J, Jenkins PR, and Richardson AL. 1990. Altered hepatic clearance and killing of *Candida albicans* in the isolated perfused mouse liver model. **Infect Immun** 58: 2869 – 2874.
67. Kobayashi H, Shibata N, Mitobe H, Ohkubo Y, and Suzuki S. 1989. Structural study of phosphomannan of yeast – form cells of *Candida albicans* J – 1012 strain with special reference to application of mild acetolysis. **Arch Biochem Biophys** 272: 364 – 375.

68. Shibata M, Kobayashi H, Tojo M, and Suzuki S. 1986. Characterization of phosphomannan – protein complexes isolated from viable cells of yeast and mycelial forms of *Candida albicans* NIH B – 792 strain by action of Zymolyase 100T. **Arch Biochem Biophys** 251: 697 – 701.
69. Shibata n, Hisamichi K, Kikuchi T, Kobayashi H, Okawa Y, and Suzaki S. 1992. Sequential nuclear magnetic resonance assignment of β - 1,2 – linked mannanoligosacchrides isolated from the phosphomannan of the pathogenic yeast *Candida albicans* NIH B – 792 strain. **Biochem** 31: 5680 – 5686.
70. Sanjua'n R, Zueco J, Roberto S, Font de Mora J, and Sentandreu R. 1995. Identification of glucan – mannoprotein complexes in the cell wall of *Candida albicans* using a monoclonal antibody that reacts with a (1,6) – β – glucan epitope. **Microbiol** 141 : 1545 – 1551.
71. Elorza MV, Mormeneo S, Garcia de la Cruz F, Gimieno C, and Sentandreu R. 1989. Evidence for the formation of covalent bonds between macromolecules in the domain of the walls of *C. albicans* mycelial cells. **Biochem Biophys Res Commun** 162 : 1118 – 1121.
72. Elorza MV, de la Cruz G, San JR, Marcilla A, Rico H, Mormeneo S, and Sentandreu R. 1993. Linkages between macromolecules in *Candida albicans* cell wall. **Arch Med Res** 24(3) : 305 – 10.
73. Cassone A. 1989. Cell wall of *Candida albicans* : its functions and its impact on the host. **Curr Top Med Mycol** 3: 248 – 314.
74. Shepherd MG. 1987. Cell envelope of *Candida albicans*. **Crit Rev Microbiol** 15: 7 – 25.
75. Ataoglu H, Zeuco J, and Sentandreu R. 1993. Characterization of epitopes recognized by *Candida* factor 1 and 9 antisera by use of *Saccharomyces cerevisiae mnn* mutants. **Infect Immun** 63: 569 – 572.
76. Li RK, and Cutler JE. 1993. Chemical definition of an epitope/adhesin molecule on *Candida albicans*. **J Biol Chem** 268 : 18293 – 18299.

86. Sentandreu R, Martinez JP, Elorza MV, and Morneneo S. 1991. Relationships between dimorphism, cell wall structure, and surface activities in *Candida albicans*. In R.Prasad (ed.), ***Candida albicans: cellular and molecular biology***. Berlin, Germany : Springer – Verlag DG, 72 – 88.
87. Sentandreu R, Morneneo S, Ruiz – Herrera J. 1994. Biogenesis of the fungal cell wall. J.G.H. Wessels and F. Meinhardt (ed.), ***The Mycota I : growth, differentiation and sexuality***. Berlin, Germany: Springer – Verlag KG, 111 – 124.
88. Kapteyn JC, Montijn RC, Dijkgraaf GJ, van den Ende H, and Klis FM. 1995. Covalent association of β - 1,3 – glucan with β - 1,6 – glucosylated mannoproteins in cell walls of *Candida albicans*. ***J Bacteriol*** 177: 3788 – 3792.
89. Kapteyn JC, Montijn RC, Dijkgraaf GJ, and Klis FM. 1994. Identification of β - 1,6 – glucosylated cell wall proteins in yeast and hyphal forms of *Candida albicans*. ***Eur J Cell Biol*** 65: 402 – 407.
90. Kapteyn JC, Montijn RC, Dijkgraaf GJ, and Klis FM. 1995. Covalent association of β - 1,3 – glucan with β - 1,6 – glucosylated mannoproteins in cell walls of *Candida albicans*. ***J Bacteriol*** 177: 3788 – 3792.
91. Klis FM. 1994. Review: Cell wall assembly in yeast. ***Yeast*** 10: 851 – 869.
92. Klis FM, Caro LHP, Vosen JH, Kapteyn JC, Ram ARF.J, Montijn, RC, Van Berkel MAA, Van Den Ende H. 1997. Identification and characterization of a major building block in the cell wall of *Saccharomyces cerevisiae*. ***Biochem Soc Trans*** 25: 856 – 860.
93. Kolla'r R, Reinhold BB, Petr'akov'a E, Yeh II HJC, Ashwell G, Grgonov'a J, Kapteyn JC, Klis FM, and Cabib E. Architecture of the yeast cell wall. ***J Biol Chem***, in press.
94. Ballou CE. 1976. Structure and biosynthesis of the mannan component of the yeast cell envelope. ***Advan Microbial Phys*** 14: 93 – 158.

95. Segal E, Lehrer N, Ofek I. 1982. Adherence of *Candida albicans* to human vaginal epithelial cells: inhibition by amino sugars. **Experimental Cell Biology** 50: 13 – 17.
96. Kuo S-C, Lampen JO. 1974. Tunicamycin – an inhibitor of yeast glycoprotein synthesis. **Biochem Biophys Res Commun** 58: 287 – 295.
97. Cassone A, Marconi P, and Bistoni F. 1987. Cell wall of *Candidia albicans* and host response. **Crit Rev Microbiol** 15: 87 – 98.
98. Douglas LJ, McCourtie J. 1983. Effect of tunicamycin treatment on the adherence of *Candida albicans* to human buccal epithelial cells. **FEMS Microbiol Lett** 16: 199 – 202.
99. Scaringi L, Marconi P, Boccanera M, Tissi L, Bistoni F, and Cassone A. 1988. Cell wall components of *Candida albicans* as immunomodulators: induction of natural killer and macrophage – mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. **J Gen Microbiol** 134: 1265 – 1274.
100. Poulain DV, Hopwood V, and Vernes A. 1985. Antigenic variability of *Candida albicans*. **Crit Rev Microbiol** 12: 223 – 270.
101. Hazen KC. 1990. Cell surface hydrophobicity of medically important fungi, specially *Candida* species. In R.j. Doyle and M. Rosenberg (ed.), **Microbial cell surface hydrophobicity. American Society for Microbiology**, Washington, D.C.: 249 – 295.
102. Bobichon H, Gache D, and Bouchet P. 1994. Ultrarapid cryofixation of *Candida albicans*: evidence for a fibrillar reticulated external layer and mannan channels within the cell wall. **Cryo – Lett** 15: 161 – 172.
103. Hazen KC, Hazen BW, and Allietta MM. 1995. Cell wall anchoring to cytoplasmic membrane of *Candida albicans*. **FEMS Microbiol Lett** 125: 143 – 148.
104. Kusamichi M, Monodane T, Tokunaga M, and Koike H. 1990. Influence of surrounding media on preservation of cell wall structure of *Candida albicans* revealed by low temperature scanning electron microscopy. **J Electron Microsc** 39: 477 – 486.

- 105.Odds FC. 1988. Morphogenesis in *Candida albicans*. **Crit Rev Microbiol** 12: 45 – 93.
- 106.Gardiner RB, Canton M, and Day AW. 1982. Serological studies on the fimbriae of yeast and yeast-like species. **Bot Gaz** 143:534 – 541.
- 107.Yu L, Lee KK, Ens K, Doig PC, Carpenter MR, Staddon W, Hodges RS, Paranchych W, and Irvin RT. 1994. Partial characterization of a *Candida albicans* fimbrial adhesin. **Infect Immun**. 62: 2834 – 2842.
- 108.Hazen KC, and Hazen BW. 1992. Hydrophobic surface protein masking by the opportunistic fungal pathogen *Candida albicans*. **Infect Immun** 60: 1499 – 1508.
- 109.Yu L, Lee KK, Hodges RS, Panachych W, and Irvin RT. 1994. Adherence of *Pseudomonas aeruginosa* and *Candida albicans* to glycosphingolipis (asialo – GM₁) receptors is achieved by a conserved receptor – binding domain present on their adhesins. **Infect Immun** 62: 5213 – 5219.
- 110.Lee KK, Yu L, Macdonald DL, Paranchych W, Hodges RS, and Irvin RT. 1996. Anti – adhesin antibodies that recognize a receptor – binding motif (adhesintope) inhibit pilus / fimbrial – mediated adherence of *Pseudomonas aeruginosa* and *Candida albicans* to asialo - GM₁ receptors and human buccal epithelial cell surface receptors. **Can J Microbiol** 42: 479 – 486.
- 111.Yu L, Lee KK, Sheth HB, Lane – Bell P, Srivastava G, Hindsgaul O, Paranchych W, Hodges RS, and Irvin RT. 1994. Fimbria – mediated adherence of *Candida albicans* to glycosphingolipid receptors on human buccal epithelial cells. **Infect Immun** 62: 2843 – 2848.
- 112.Yu L, Lee KK, Paranchych W, Hodges RS, and Irvin RT. 1996. Use of synthetic peptides to confirm that the *Pseudomonas aeruginosa* PAK pilus adhesin and the *Candida albicans* fimbrial adhesin possess a homologous receptor – binding domain. **Mol Microbiol** 19: 1107 – 1116.
- 113.Clerin J, Ray J.M, Schisler NJ, Day AW, Stetler – Stevenson WG, and Laudenbach DE. 1996. Fungal fimbriae are composed of collagen. **EMBO** 15: 4445 – 4453.

114. Xu J, and Day AW. 1992. Multiple forms of fimbriae on the sporidia of corn smut, *Ustilago maydis*. **Int J Plant Sci** 153: 531 – 540.
115. Howard D. 1981. Mechanisms of resistance in the systemic mycoses. Chapter 19. In Nahmias, A.J., and R.J. O' Reilly (eds), **Immunology of human infections** New York, Plenum Press, pp. 475 – 494.
116. Ausiello CM, Palma C, Spagnoli GC, Piazza A, Casciani CU, and Cassone A. 1989. Cytotoxic effectors in human peripheral blood mononuclear cells induced by a mannoprotein complex of *Candida albicans* : a comparison with interleukin 2 – activated killer cells. **Cell Immunol** 121: 349 – 359.
117. de Bernardis R, Boccanera M, Adriani D, Spreghini E, Santoni G, and Cassone A. 1997. Protective role of antimannan and anti – aspartyl proteinase antibodies in an experimental model of *Candida albicans* vaginitis in rats. **Infect Immun** 65: 3399 – 3405.
118. Goudswaard J, van der Donk JA, Noordzij A. *et al.* 1978. Protein A reactivity of various mammalian immunoglobulins. **Scand, J Immunol** 8: 21 – 28.
119. Dee TH, and Rytel MW. 1975. Clinical application of counterimmunoelectrophoresis in detection of *Candida* sera precipitins. **J Lab Clin Med** 85: 161 – 166.
120. Brooks GF, Butel JS, and Ornston LN. 1991. Opportunistic Mycoses. Jawetz, Melnick & Adelberg's **Medical Microbiology** (19th). Prentice – Hall International Inc. Published. : 323 – 326.
121. Burnie JP, and Williams JD. 1985. Evaluation of the Ramco latex agglutination test in the early diagnosis of systemic candidiasis. **Eur J Clin Microbiol** 4: 98 – 101.
122. Gentry LO, Wikinson ID, Les AS, and Price MF. 1983. Latex agglutination test for detection of *candida* antigen in patients with disseminated disease. **Eur J Clin Microbiol** 2: 122 – 128.
123. Brooks GF, Butel JS, and Ornston LN. 1991. Opportunistic Mycoses. Jawetz, Melnick & Adelberg's **Medical Microbiology** (19th). Prentice – Hall International Inc. Published. : 323 – 326.

124. deRepentigny L, and Reiss E. 1984. Current trends on immunodiagnosis of candidiasis and aspergillosis. **Rev Infect Dis** 6: 301 – 309.
125. Araj GF, Hopfer RL, *et al.* 1982. Diagnostic value of the enzyme – linked immunosorbent assay for detection of *Candida albicans* antigen in sera of cancer patients. **J Clin Microbiol** 16: 46 – 52.
126. Navarro D, Monzonis E, Lopez - Ribot JL, Sepulveda P, Casanova M, Nogueira JM, and Martinez JP. 1993. Diagnosis of systemic candidiasis by enzyme immunoassay detection of specific antibodies to mycelial phase cell wall and cytoplasmic candidal antigens. **Eur J Clin Microbiol Infect Dis** 12: 839 – 846.
127. Segal, E., and D. Elad. *Candida* species and *Blastoschizomyces capitatus* in Topley & Wilson's Microbiology and Microbial Infections. Volume 4, 9thed. Collier L. *et al.* The Bath Press, Avon, Great Britain.
128. Ashman RB, Papadimitriou JM, Ott AK, and Warmington JR. 1990. Review: Antigens and Immune Responses in *Candida albicans* **Infect Immunol. Cell Biol** 68:1-13.
129. Pfaller MA. 1996. Nosocomial Candidiasis : Emerging Species, reservoirs, and Modes of Transmission. **CID** 22(Suppl 2) : s89 – s92.
130. Costantino PJ, Gare NF, and Warmington JR. 1995. Humoral Immune Responses to Systemic *Candida albicans* Infection in Inbred Mouse Strains. **Immunol. Cell Biol** 73:125-33.
131. Macdonald F, and Odds FC. 1980. Inducible protease of *Candida albicans* in diagnostic serology and in the pathogenesis of systemic candidiasis. **J Med Microbiol** 13: 423 – 435.
132. Sundstrom P, Jensen J, and Balish E. 1994. Humoral and cellular immune response to enolase after alimentary tract colonization or intravenous immunization with *Candida albicans*. **J Infect Dis** 170 : 390 – 395.
133. Bernard E, Christiansen KJ, Tsand SF, Kiehn TE, and Armstrong D. 1981. Rate of arabinitol production by pathogenic yeast species. **J Clin Microbiol** 14: 189 – 194.

134. Manning – Zweerink M, Maloney CS, Mitchell TG, and Weston H. 1986. Immunoblot analyses of *Candida albicans* – associated antigens and antibodies in human sera. **J Clin Microbiol** 23(1) : 46 – 52.
135. Ishiguro A, Homma M, Sukai T, Higashide K, Torii S, and Tanaka K. 1992. Immunoblotting analysis of sera from patients with candidal vaginitis and healthy females. **J Med Vet Mycol** 30 : 281 – 292.
136. Matthews RC, Hodgetts S, Burnie JP. 1994. Preliminary assessment of a human recombinant antibody to hsp 90 in the treatment of murine invasive candidiasis. **J Infect Dis** 171 : 1668 – 1671.
137. Ishiguro A, Kanbe T, Doi M, Homma M, Horibe K, and Tanaka K. 1996. Detection of IgG Antibodies Specific for *Candida albicans* Antigens in Children with Acute Lymphoblastic Leukemia. **Jpn J Med Mycol** 37:167-73.
138. Casanova M, Lopez – Ribot L, Monteagudo C, Llombart – Bosch R, Sentandreu R, and Martinez JP. 1992. Identification of a 58 – kilodalton cell surface fibrinogen – binding mannoprotein from *Candida albicans*. **Infect Immun** 60: 4898 – 4906.
139. Sep'uleda P, Lopez – Ribot JL, Murgui A, Canton E, Navarro D, and Martinez JP. 1998. *Candida albicans* fibrogen binding protein : expression in clinical strains and immunogenicity in patients with systemic candidiasis. **Int Microbiol** 1: 209 – 216.
140. Gomea MJ, Maras B, Barca A, La Valle R, Barra D, and Cassone A. 2000. Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen *Candida albicans*. **Infect Immun** 68 (2) : 694 – 701.
141. La Valle R, Sandina S, Gomez MJ, Mondello R, Romagnoli G, Nisni R, and Cassone A. 2000. Generation of a recombinant 65 – Kilodalton mannoprotein, a major antigen target of cell – mediated immune response to *Candida albicans*. **Infect Immun** 68(12) : 6777 – 6784.

142. Akashi T, Homma M, Kanbe T, and Tanaka K. 1993. Ultrastructure of proteinase - secreting cells of *Candida albicans* studied by alkaline bismuth staining and immunocytochemistry. **J Gen Microbiol** 139 : 2185 – 2195.
143. Kanbe T, Morishita M, Ito K, Tomita K, Utsunomiya K, and Ishiguro A. 1996. Evidence for the Presence of Immunoglobulin E Antibodies Specific to the Cell Wall Phosphomannoproteins of *Candida albicans* in Patients with Allergies. **Clin Diagn Lab Immunol** 3:645-50.
144. Emori TG, Gaynes RP, 1993. An overview of nosocomial infections, including the role of the microbiology laboratory. **Clin Microbiol Rev** 6: 428 – 442.
145. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. **Nature** (London). 227: 680 – 685.
146. สุวิชาน มนแพวงสานนท์. 2001. วิเคราะห์ข้อมูลทางสถิติด้วย SPSS for Windows. Published by Se – Education public co.ltd.
147. ทัสสนี นุชประยูร และ เต็มศรี ชำนิจารกิจ. 1999. สถิติในวิจัยทางการแพทย์, พิมพ์ครั้งที่ 2. กรุงเทพฯ. สำนักพิมพ์จุฬาลงกรณ์มหาวิทยาลัย
148. Ellsworth JH, *et al.* 1977. Comparative serological and cutaneous reactivity of candidal cytoplasmic proteins and mannan separated by affinity for concanavalin A. **J Clin Microbiol** 5: 91 – 99.
149. Jones JM. 1980, Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of *Candida* in rabbits, mice, and humans. **Infect Immun** 30: 78 – 89.
150. Monson TP, and Wilkinson KP. 1981. Mannose in body fluids as an indicator of invasive candidiasis. **J Clin Microbiol** 14: 557 – 562.
151. Gold JWM, Wong B, Bernard EM, Kiehn TE, and Armstrong D. 1983. Serum arabinitol concentrations and arabinitol / creatinine ratios in invasive candidiasis. **J Infect Dis** 147: 504 – 513.
152. Lehtonen L, Anttila VJ, *et al.* 1996. Diagnosis of disseminated candidiasis by measurement of urine D – arabinitol/ L – arabinitol ratio. **J Clin Micro** 34: 2175 – 2179.

163. Matthews RC, and Burnie JP. 1988. Diagnosis of systemic candidiasis by an enzyme – linked dot immunobinding assay for a circulating immunodominant 47 – kilodalton antigen. **J Clin Microbiol** 26: 459 – 463.
164. Matthews RC, Burnie JP, and Tabaqchali S. 1987. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to *Candida albicans*. **J Clin Microbiol** 25: 230 – 237.
165. Matthews RC, Burnie JP, and Tabaqchali S. 1984. Immunoblot analysis of the serological response in systemic candidiasis. **Lancet ii** : 1415 – 1418.
166. Liu J-H, and Reid DM. 1994. A cDNA clone from sunflower hypocotyl homologous to *C. reesei* S-phase specific gene. **EMBL** accession number L31645.
167. Matthews RC, *et al.* 1991. Autoantibody to hsp90 can mediate protection against systemic candidosis. **Immunol** 74: 20 – 24.
168. Elliot TSJ. 1988. Intravascular – device infections. **J Med Microbiol** 27: 161 – 167.
169. Kauffman SHE. 1990. Heat shock proteins and the immune response. **Immunol Today** 11: 129 – 136.
170. Tronshin F, Bouchara JP, Robert R, and Senet JM. 1988. Adherence of *Candida albicans* germ tubes to plastic : ultrastructural and molecular studies of fibrillar adhesins. **Infect Immun** 56: 1987 – 1993.
171. Zoller L, Kramer I, Kappe R, and Sonntag H-G. 1991. Enzyme immunoassays for invasive *Candida* infections: reactivity of somatic antigens of *Candida albicans*. **J Clin Microbiol** 29(9): 1860 – 1867.



APPENDIX

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

Appendix

1. Separating gel (14%)

1.5 M Tris pH 8.8	7.50 ml
30% Acryl : Bis	14.10 ml
10% SDS	0.30 ml
DW	7.90 ml
TEMED	0.03 ml
14% Ammonium peroxide	0.15 ml

2. Stacking gel

1 M Tris pH 6.8	675 μ l
30 %Acryl : Bis	750 μ l
10% SDS	50 μ l
DW	3.7 ml
TEMED	5 μ l
14% Ammonium peroxide	25 μ l

3. Acrylamide : Bis

Acrylamide	30 g
Bis (N,N' – methylenebisacrylamide)	0.8 g
DW	70 ml
Adjust to 100 ml by adding DW to 100 ml	

4. 1.5 M Tris pH 8.8

Tris – hydroxymethyl	18.2 g
HCl – N aminomethane	28 g
DW	58.7 ml
Adjust to pH 8.8 by HCl and adding DW to 100 ml	

5. 1 M Tris pH 6.8

Tris – hydroxymethyl	12.1 g
HCl – N aminomethane	95 g
DW	58.7 ml
Adjust to pH 6.8 by HCl and adding DW to 200 ml	

6. SDS – Electrode Buffer

Tris – hydroxymethyl	3 g
Glycine	14.4 g
SDS	1 g
DW to 1 L	

7. Sample Buffer

1 M Tris pH 6.8	4 ml
SDS	0.6 g
75 % glycerol	5.1 ml
0.2% BPB (β – mercaptoethanol)	0.4 ml

8. Blotting Buffer

Tris – hydroxymethyl	7.26 g
Glycine	33.72 g
Methanol	600 ml
DW	2.4 L

9. Coomassie Brilliant Blue R

Brilliant Blue R	0.4 g
Methanol	200 ml
Acetic acid	40 ml
DW	400 ml

10. Fixation solution

Methanol	50 ml
Acetic acid	10 ml
DW	40 ml

11. Destaining solution

Methanol	5 ml
Acetic acid	7 ml
DW	88 ml

12. PBS Buffer (10x)

NaCl	80 g
KCl	2 g
KH ₂ PO ₄	1.4 g
Na ₂ HPO ₄	9.1 g
DW	1000 ml

13. Coating Buffer (200 ml)

Na ₂ CO ₃	0.318 g
NaHCO ₃	0.586 g
NaN ₃	0.04 g
DW	200 ml

14. Citric acid

Citric acid	3.65 g
Na ₂ HPO ₄	4.735 g
DW	500 ml

15. Binding buffer (0.02 M Sodium Phosphate, pH 7.0 (200 ml))

NaHPO ₄	0.5523 g
DW	100 ml
Adjust to pH 7.0 , DW to 200 ml	

16. Elution buffer (1 M acetic acid (200 ml))

17.48 M Acetic acid	14.3 ml
DW	235.7 ml

17. 1 M Tris – HCl, pH 9.0 (1 litre)

Tris – Base	121.14 g
DW	500 ml
Adjust to pH 9.0, DW to 1000 ml.	

18. Amido black

Amido black	0.01 g
Methanol	45 ml
Acetic acid	10 ml
DW	45 ml

19. Destain solotion (amido black)

Methanol	90 ml
Acetic acid	2 ml
DW	8 ml

20. 14% Ammonium peroxide (2 ml)

Ammonium peroxide	40 mg
DW	2 ml

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

CURRICULUM VITAE

Miss Patcharee Kumarnjassadakul was born on March 2, 1977 in Bangkok, Thailand. She graduated with the Bachelor degree of Science in Medical Technoloy from the Faculty of Allied Health Science, Chulalongkorn University in 1997.



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย